Metrics as of 10/13/2026, 08:47 AM (Berlin time), refresh in progress.
Xenon Pharmaceuticals Stock
Xenon Pharmaceuticals Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- CEO
- Ian C. Mortimer
- Employees
- 364
- Market cap
- $3.4 B
- IPO
- 05/11/2014
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. Headquartered in Burnaby, Canada, the company was established in 1996. With 364 employees, Xenon Pharmaceuticals focuses on…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Xenon Pharmaceuticals stock: price history
1D
-2.1%
1W
-4.1%
1M
-40.2%
6M
-40.9%
YTD
-21.8%
1Y
-12.3%
2Y
-14.9%
5Y
+6.7%
10Y
+324.4%
Next earnings date
Next earnings date
02/11/2026 (in 16 days)
Volatility around earnings
~6% weaker price swings than usual
Ask the agents about Xenon Pharmaceuticals
Analyst assessment of Xenon Pharmaceuticals
PRICE TARGET LOW
US$46.00
CONSENSUS
US$68.63
MEDIAN
US$67.00
PRICE TARGET HIGH
US$90.00
0
STRONG BUY
21
BUY
1
HOLD
0
SELL
0
STRONG SELL
22
TOTAL · Buy
As of: 18/09/2026
Xenon Pharmaceuticals stock metrics
P/E
-7.4
P/B
2.81
EV/EBITDA
-7.87
RETURN ON EQUITY
-8.9%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
93.9%
FLOAT SHARES
90,758,318
AVG. DAILY VOLUME (30D)
2,176,267
Insider transactions (SEC)
Kelly Thomas Patrick
Kelly Thomas Patrick
MORTIMER IAN
Svoronos Dawn
KENNEY CHRISTOPHER JOHN
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.1%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Xenon Pharmaceuticals stock
What does Xenon Pharmaceuticals do?
Xenon Pharmaceuticals Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in Canada.
The CEO is Ian C. Mortimer, the company employs around 364 people.
The IPO was on 05/11/2014; the stock trades on NASDAQ under the ticker XENE.
What do analysts say about Xenon Pharmaceuticals stock?
22 analysts rate the stock, the consensus is Buy (as of 18/09/2026).
The average price target is US$68.63, ranging from US$46.00 to US$90.00, with a median of US$67.00.
This is an external assessment, not a statement by Market Jury.
When does Xenon Pharmaceuticals report next?
The next earnings date is 02/11/2026.
Around past earnings, price swings were roughly -6% stronger than usual.
Does Xenon Pharmaceuticals pay a dividend?
No, Xenon Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Xenon Pharmaceuticals?
Comparable stocks include AbCellera Biologics, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Xenon Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Xenon Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.